JCR Pharmaceuticals Co., Ltd. announced that it has achieved the first research milestone criterion in a collaboration with Alexion, AstraZeneca Rare Disease ("Alexion") to develop an undisclosed initial therapeutic molecule that applies JCR's proprietary J-Brain Cargo®?, blood-brain barrier penetration technology, for the treatment of a neurodegenerative disease. The achievement of a predefined research milestone triggers a milestone payment to JCR. JCR recently strengthened its collaboration with Alexion to address unmet needs by initiating a second research collaboration in December 2023 to apply the same technology to oligonucleotide therapeutics.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
814 JPY | +2.13% | +0.74% | -30.55% |
Mar. 21 | US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak | MT |
Mar. 21 | JCR Pharmaceuticals Achieves Neurodegenerative Treatment Research Milestone With Alexion | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.55% | 632M | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion